| Methods |
Randomized, parallel, double‐blind, placebo‐
controlled study. |
| Participants |
N=41;
Geographic region: Finland
Mean age: 46.8
Discontinuations/Not available to follow‐up: 6, finasteride=4, placebo=2 |
| Interventions |
Finasteride 5 mg daily (n=31) vs. placebo (n=10).
Study duration: 12 months |
| Outcomes |
Symptomatic changes ‐ Prostatitis Symptom Severity Index, prostatism score, pain evaluation; uroflowmetry; prostate specific antigen level; prostate volume; adverse events. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
B ‐ Unclear |
